MDGL 213.41 Madrigal Pharmaceuticals, Inc.
| Range: | 119.76-299.98 | Vol Avg: | 278351 | Last Div: | 0 | Changes: | 3.57 |
| Beta: | -0.45 | Cap: | 4.65B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Feb 06 2007 | Empoloyees: | 376 | ||
| CUSIP: | 558868105 | CIK: | 0001157601 | ISIN: | US5588681057 | Country: | US |
| CEO: | Mr. William J. Sibold | Website: | https://www.madrigalpharma.com | ||||
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Stock Details
MDGL 336
Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
Yasmeen Rahimi·Wed May 29 2024
Piper Sandler
MDGL 390
Madrigal Pharmaceuticals (MDGL) PT Lowered to $390 at H.C. Wainwright
Ed Acre·Thu May 09 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow